Contribution of Automated Antigen Tests, the LumiraDx Ag Test in the Response during the Second Wave of the COVID-19 Pandemic in Bangui  

作　　者：Clotaire Donatien Rafaï Pierre Somse Wilfrid Sylvain Nambei Ernest Lango-Yaya Marie-Roseline Darnycka Belizaire Ulrich Vickos Narcisse Patrice Komas Oscar Senzongo Luc Salva Heredeibona Ulrich Jeffrey Kotemossoua Rabbi Mermoz Senekian Simon Pounguinza Jephté Estimé Kaleb Kandou Christian-Diamant Mossoro-Kpinde Laurent Bélec Jean De Dieu Longo Norbert Richard Ngbale Abdoulaye Sepou François-Xavier Mbopi-Keou Gérard Grésenguet Boniface Koffi Clotaire Donatien Rafaï;Pierre Somse;Wilfrid Sylvain Nambei;Ernest Lango-Yaya;Marie-Roseline Darnycka Belizaire;Ulrich Vickos;Narcisse Patrice Komas;Oscar Senzongo;Luc Salva Heredeibona;Ulrich Jeffrey Kotemossoua;Rabbi Mermoz Senekian;Simon Pounguinza;Jephté Estimé Kaleb Kandou;Christian-Diamant Mossoro-Kpinde;Laurent Bélec;Jean De Dieu Longo;Norbert Richard Ngbale;Abdoulaye Sepou;François-Xavier Mbopi-Keou;Gérard Grésenguet;Boniface Koffi(National Laboratory of Clinical Biology and Public Health, Bangui, Central African Republic;Faculty of Health Sciences, University of Bangui, Bangui, Central African Republic;Ministry of Health and Population, Bangui, Central African Republic;World Health Organization, Bangui, Central African Republic;Institut Pasteur de Bangui, Bangui, Central African Republic;Virology Laboratory, Georges Pompidou European Hospital, Université Paris Cité, Paris, France;Hôpital Communautaire of Bangui, Bangui, Central African Republic;Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon)

机构地区：[1]National Laboratory of Clinical Biology and Public Health, Bangui, Central African Republic [2]Faculty of Health Sciences, University of Bangui, Bangui, Central African Republic [3]Ministry of Health and Population, Bangui, Central African Republic [4]World Health Organization, Bangui, Central African Republic [5]Institut Pasteur de Bangui, Bangui, Central African Republic [6]Virology Laboratory, Georges Pompidou European Hospital, Université Paris Cité, Paris, France [7]Hôpital Communautaire of Bangui, Bangui, Central African Republic [8]Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon

出　　处：《Journal of Tuberculosis Research》2023年第4期173-183,共11页结核病研究（英文）

摘　　要：Context and objective: The COVID-19 pandemic has become a major public health problem and has mobilized many innovative means of diagnosis. The Central African Republic is not spared. The emergence of variants and their impact require health monitoring despite the obligation of vaccination. The purpose of this campaign was to determine the circulation of pending second-wave variants. Patients and Methods: A second mass screening campaign took place from 02 to 22 July 2021 in the main land and river entry points of Bangui (Exit North-PK12, Exit South-PK9, Port Beach) and at the LNBCSP. Antigenic and RT-PCR tests carried out on nasopharyngeal samples made it possible to select strains which were finally sequenced. Results: Of 2687 participants included in the study, 53 (1.97%) were positive for SARS-CoV-2. Thirteen (1.53%) were male and 40 (2.18%) female. The analyses carried out on the LumiraDx analyzer were positive for 109 samples against 53 on the RT-PCR. The prevalence was higher in the most tested age groups (30 to 50 years) with two clusters identified. B.1.617.2 (Delta) variants were predominant (57%). Conclusion: SARS-CoV-2 continues to circulate. The acquisition of automated antigenic tests (LumiraDx&#174) with sensitivity and specificity close to those of the reference test (RT-PCR) will allow better mass diagnosis for an optimization of the surveillance of COVID-19 in our countries with limited resources. The predominance of the B.1.617.2 (Delta) variant would suggest a third wave in the Central African Republic.Context and objective: The COVID-19 pandemic has become a major public health problem and has mobilized many innovative means of diagnosis. The Central African Republic is not spared. The emergence of variants and their impact require health monitoring despite the obligation of vaccination. The purpose of this campaign was to determine the circulation of pending second-wave variants. Patients and Methods: A second mass screening campaign took place from 02 to 22 July 2021 in the main land and river entry points of Bangui (Exit North-PK12, Exit South-PK9, Port Beach) and at the LNBCSP. Antigenic and RT-PCR tests carried out on nasopharyngeal samples made it possible to select strains which were finally sequenced. Results: Of 2687 participants included in the study, 53 (1.97%) were positive for SARS-CoV-2. Thirteen (1.53%) were male and 40 (2.18%) female. The analyses carried out on the LumiraDx analyzer were positive for 109 samples against 53 on the RT-PCR. The prevalence was higher in the most tested age groups (30 to 50 years) with two clusters identified. B.1.617.2 (Delta) variants were predominant (57%). Conclusion: SARS-CoV-2 continues to circulate. The acquisition of automated antigenic tests (LumiraDx&#174) with sensitivity and specificity close to those of the reference test (RT-PCR) will allow better mass diagnosis for an optimization of the surveillance of COVID-19 in our countries with limited resources. The predominance of the B.1.617.2 (Delta) variant would suggest a third wave in the Central African Republic.

关 键 词：COVID-19 Automated Antigen Testing 

分 类 号：R73[医药卫生—肿瘤]